A5043274210- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Computational Drug Discovery Methods
- Photosynthetic Processes and Mechanisms
- Algal biology and biofuel production
- Polar Research and Ecology
Westlake University
2022-2023
The 3C-like protease (3CLpro) is an essential enzyme for the replication of SARS-CoV-2 and other coronaviruses thus a target coronavirus drug discovery. Nearly all inhibitors 3CLpro reported so far are covalent inhibitors. Here, we report development specific, noncovalent 3CLpro. most potent one, WU-04, effectively blocks replications in human cells with EC50 values 10-nM range. WU-04 also inhibits SARS-CoV MERS-CoV high potency, indicating that it pan-inhibitor showed anti-SARS-CoV-2...
Abstract The ketocarotenoid fucoxanthin and its derivatives can absorb blue–green light enriched in marine environments. Fucoxanthin is widely adopted by phytoplankton species as a main light-harvesting pigment, contrast to land plants that primarily employ chlorophylls. Despite supreme abundance the oceans, last steps of biosynthesis have remained elusive. Here, we identified carotenoid isomerase-like protein CRTISO5 diatom synthase related cis–trans isomerase CRTISO from but harbors...
Abstract The SARS-CoV-2 virus is the causal agent of ongoing pandemic coronavirus disease 2019 (COVID-19). There an urgent need for potent, specific antiviral compounds against SARS-CoV-2. 3C-like protease (3CLpro) essential enzyme replication and other coronaviruses, thus a target drug discovery. Nearly all inhibitors 3CLpro reported so far are covalent inhibitors. Here, we report development specific, non-covalent 3CLpro. most potent one, WU-04, effectively blocks replications in human...